Business Wire

Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier

“We believe the findings from this large-scale, real-world study add meaningfully to the substantial body of data demonstrating the clinical utility of the Decipher Prostate test,” said Michael ...
Business Wire

New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that new data from a large, randomized phase 3 trial reinforce the value of the Decipher Prostate Genomic ...
ascopubs.org

Health Related Quality of Life of Prostate Cancer Patients: Assessment Using the Short Form 12 Health Survey and Patient Oriented Prostate Utility Scale

Health System Strengthening Strategies for Improved Cancer Control in Sub-Saharan Africa: A Case of the International Cancer Institute's Blueprint for Innovative Healthcare Access Program in Western ...
ascopubs.org

Association of risk of clinical recurrence (CR) and prostate cancer death (PCD) with a 17-gene genomic prostate score (GPS) value <20.

This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does not include a full text component.